1
|
von Deimling M, Mertens LS, Furrer M, Li R, Tendijck GAH, Taylor J, Crocetto F, Maas M, Mari A, Pichler R, Moschini M, Tully KH, D'Andrea D, Laukhtina E, Del Giudice F, Marcq G, Velev M, Gallioli A, Albisinni S, Mori K, Khanna A, Rink M, Fisch M, Minervini A, Black PC, Lotan Y, Spiess PE, Kiss B, Shariat SF, Pradere B. The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer. BJU Int 2024. [PMID: 38470089 DOI: 10.1111/bju.16319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/13/2024]
Abstract
OBJECTIVE To investigate the optimal number of induction chemotherapy cycles needed to achieve a pathological response in patients with clinically lymph node-positive (cN+) bladder cancer (BCa) who received three or four cycles of induction chemotherapy followed by consolidative radical cystectomy (RC) with pelvic lymph node dissection. PATIENTS AND METHODS We included 388 patients who received three or four cycles of cisplatin/gemcitabine or (dose-dense) methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC), followed by consolidative RC for cTanyN1-3M0 BCa. We compared pathological complete (pCR = ypT0N0) and objective response (pOR = yp ≤T1N0) between treatment groups. Predictors of pCR and/or pOR were assessed using uni- and multivariable logistic regression analysis. The secondary endpoints were overall (OS) and cancer-specific survival (CSS). We evaluated the association between the number of induction chemotherapy cycles administered and survival outcomes on multivariable Cox regression. RESULTS Overall, 101 and 287 patients received three or four cycles of induction chemotherapy, respectively. Of these, 72 (19%) and 128 (33%) achieved pCR and pOR response, respectively. The pCR (20%, 18%) and pOR (40%, 31%) rates did not differ significantly between patients receiving three or four cycles (P > 0.05). The number of cycles was not associated with pCR or pOR on multivariable logistic regression analyses. The 2-year OS estimates were 63% (95% confidence interval [CI] 0.53-0.74) and 63% (95% CI 0.58-0.7) for patients receiving three or four cycles, respectively. Receiving three vs four cycles was not associated with OS and CSS on uni- or multivariable Cox regression analyses. CONCLUSION Pathological response and survival outcomes did not differ between administering three or four induction chemotherapy cycles in patients with cN+ BCa. A fewer cycles (minimum three) may be oncologically sufficient in patients with cN+ BCa, while decreasing the wait for definitive local therapy in those patients who end up without a response to chemotherapy. This warrants further validation.
Collapse
Affiliation(s)
- Markus von Deimling
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Laura S Mertens
- Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Marc Furrer
- Department of Urology, University Hospital of Bern, University of Bern, Bern, Switzerland
- Department of Urology, Solothurner Spitäler AG, Kantonsspital Olten and Bürgerspital Solothurn, Switzerland
| | - Roger Li
- Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - Guus A H Tendijck
- Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Jacob Taylor
- Department of Urology, University of Texas Southwestern, Dallas, TX, USA
| | - Felice Crocetto
- Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", Naples, Italy
| | - Moritz Maas
- Department of Urology, Eberhard Karls University Tübingen, Tübingen, Germany
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
| | - Andrea Mari
- Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, Careggi Hospital, University of Florence, Florence, Italy
| | - Renate Pichler
- Department of Urology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria
| | - Marco Moschini
- Department of Urology, Urological Research Institute, Vita-Salute San Raffaele, Milan, Italy
| | - Karl H Tully
- Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany
| | - David D'Andrea
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - Ekaterina Laukhtina
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - Francesco Del Giudice
- Department of Maternal Infant and Urologic Sciences, Policlinico Umberto I Hospital, "Sapienza" University of Rome, Rome, Italy
| | - Gautier Marcq
- Department of Urology, CHU Lille, Claude Huriez Hospital, Lille, France
- CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, University of Lille, Lille, France
| | - Maud Velev
- Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Andrea Gallioli
- Department of Urology, Fundació Puigvert, Autonomous University of Barcelona, Barcelona, Spain
| | - Simone Albisinni
- Urology Unit, Department of Surgical Sciences, Tor Vergata University Hospital, University of Rome Tor Vergata, Rome, Italy
- Service d'Urologie, Hôpital Erasme, Université Libre de Bruxelles, Bruxelles, Belgium
| | - Keiichiro Mori
- Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
| | | | - Michael Rink
- Department of Urology, Marienkrankenhaus, Hamburg, Germany
| | - Margit Fisch
- Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Andrea Minervini
- Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, Careggi Hospital, University of Florence, Florence, Italy
| | - Peter C Black
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
| | - Yair Lotan
- Department of Urology, University of Texas Southwestern, Dallas, TX, USA
| | - Philippe E Spiess
- Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - Bernhard Kiss
- Department of Urology, University Hospital of Bern, University of Bern, Bern, Switzerland
| | - Shahrokh F Shariat
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria
- Department of Urology, University of Texas Southwestern, Dallas, TX, USA
- Department of Urology, Weill Cornell Medical College, New York, NY, USA
- Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan
- Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Benjamin Pradere
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- Department of Urology, Urosud, La Croix Du Sud Hospital, Quint-Fonsegrives, France
| |
Collapse
|
2
|
El Zarif T, Nassar AH, Pond GR, Zhuang TZ, Master V, Nazha B, Niglio S, Simon N, Hahn AW, Pettaway CA, Tu SM, Abdel-Wahab N, Velev M, Flippot R, Buti S, Maruzzo M, Mittra A, Gheeya J, Yang Y, Rodriguez PA, Castellano D, de Velasco G, Roviello G, Antonuzzo L, McKay RR, Vincenzi B, Cortellini A, Hui G, Drakaki A, Glover M, Khaki AR, El-Am E, Adra N, Mouhieddine TH, Patel V, Piedra A, Gernone A, Davis NB, Matthews H, Harrison MR, Kanesvaran R, Giudice GC, Barata P, Farolfi A, Lee JL, Milowsky MI, Stahlfeld C, Appleman L, Kim JW, Freeman D, Choueiri TK, Spiess PE, Necchi A, Apolo AB, Sonpavde GP. Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors. J Natl Cancer Inst 2023; 115:1605-1615. [PMID: 37563779 PMCID: PMC11032703 DOI: 10.1093/jnci/djad155] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Revised: 07/26/2023] [Accepted: 08/02/2023] [Indexed: 08/12/2023] Open
Abstract
BACKGROUND Treatment options for penile squamous cell carcinoma are limited. We sought to investigate clinical outcomes and safety profiles of patients with penile squamous cell carcinoma receiving immune checkpoint inhibitors. METHODS This retrospective study included patients with locally advanced or metastatic penile squamous cell carcinoma receiving immune checkpoint inhibitors between 2015 and 2022 across 24 centers in the United States, Europe, and Asia. Overall survival and progression-free survival were estimated using the Kaplan-Meier method. Objective response rates were determined per Response Evaluation Criteria in Solid Tumours 1.1 criteria. Treatment-related adverse events were graded per the Common Terminology Criteria for Adverse Events, version 5.0. Two-sided statistical tests were used for comparisons. RESULTS Among 92 patients, 8 (8.7%) were Asian, 6 (6.5%) were Black, and 24 (29%) were Hispanic and/or Latinx. Median (interquartile range) age was 62 (53-70) years. In all, 83 (90%) had metastatic penile squamous cell carcinoma, and 74 (80%) had received at least second-line treatment. Most patients received pembrolizumab monotherapy (n = 26 [28%]), combination nivolumab-ipilimumab with or without multitargeted tyrosine kinase inhibitors (n = 23 [25%]), or nivolumab (n = 16 [17%]) or cemiplimab (n = 15 [16%]) monotherapies. Median overall and progression-free survival were 9.8 months (95% confidence interval = 7.7 to 12.8 months) and 3.2 months (95% confidence interval = 2.5 to 4.2 months), respectively. The objective response rate was 13% (n = 11/85) in the overall cohort and 35% (n = 7/20) in patients with lymph node-only metastases. Visceral metastases, Eastern Cooperative Oncology Group (ECOG) performance status of 1 or higher, and a higher neutrophil/lymphocyte ratio were associated with worse overall survival. Treatment-related adverse events occurred in 27 (29%) patients, and 9.8% (n = 9) of the events were grade 3 or higher. CONCLUSIONS Immune checkpoint inhibitors are active in a subset of patients with penile squamous cell carcinoma. Future translational studies are warranted to identify patients more likely to derive clinical benefit from immune checkpoint inhibitors.
Collapse
Affiliation(s)
- Talal El Zarif
- Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA
- Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA
| | - Amin H Nassar
- Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA
| | - Gregory R Pond
- Department of Oncology, McMaster University, Hamilton, ON, Canada
| | - Tony Zibo Zhuang
- Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA
| | - Viraj Master
- Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA, USA
| | - Bassel Nazha
- Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA, USA
| | - Scot Niglio
- New York University Grossman School of Medicine, New York, NY, USA
| | - Nicholas Simon
- Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Andrew W Hahn
- University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | | | - Shi-Ming Tu
- Division of Hematology and Oncology, University of Arkansas for Medical Sciences, Winthrop P. Rockefeller Cancer Institute, Little Rock, AR, USA
| | - Noha Abdel-Wahab
- University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Assiut University Faculty of Medicine, Assiut University Hospitals, Assiut, Egypt
| | - Maud Velev
- Département d’Innovation Thérapeutique et Essais Précoces, Gustave Roussy—Paris-Saclay University, Villejuif, France
| | - Ronan Flippot
- Medical Oncology Department, Institute Gustave Roussy, Villejuif, France
| | - Sebastiano Buti
- Department of Medicine and Surgery, Oncology Unit, University Hospital of Parma, Parma, Italy
| | - Marco Maruzzo
- Oncology 1 Unit, Istituto Oncologico Veneto IOV—Istituto Di Ricovero e Cura a Carattere Scientifico, Padova, Italy
| | - Arjun Mittra
- Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
| | - Jinesh Gheeya
- Genitourinary Oncology Section, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center—James Cancer Hospital, Columbus, OH, USA
| | - Yuanquan Yang
- Genitourinary Oncology Section, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center—James Cancer Hospital, Columbus, OH, USA
| | | | - Daniel Castellano
- Department of Medical Oncology, Hospital Universitario, 12 de Octubre, Madrid, Spain
| | - Guillermo de Velasco
- Department of Medical Oncology, Hospital Universitario, 12 de Octubre, Madrid, Spain
| | - Giandomenico Roviello
- Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy
| | - Lorenzo Antonuzzo
- Clinical Oncology Unit, Careggi University Hospital, Florence, Italy
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
| | - Rana R McKay
- University of California San Diego, San Diego, CA, USA
| | - Bruno Vincenzi
- Medical Oncology Department, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy
| | - Alessio Cortellini
- Medical Oncology Department, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy
- Department of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College London, London, United Kingdom
| | - Gavin Hui
- University of California Los Angeles, Los Angeles, CA, USA
| | | | - Michael Glover
- Division of Medical Oncology, Department of Medicine, Stanford University, Stanford, CA, USA
| | - Ali Raza Khaki
- Division of Medical Oncology, Department of Medicine, Stanford University, Stanford, CA, USA
| | - Edward El-Am
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA
| | - Nabil Adra
- Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, USA
| | - Tarek H Mouhieddine
- Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Vaibhav Patel
- Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Aida Piedra
- Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | | | - Nancy B Davis
- Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Harrison Matthews
- Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA
| | - Michael R Harrison
- Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA
| | | | - Giulia Claire Giudice
- Department of Medicine and Surgery, Oncology Unit, University Hospital of Parma, Parma, Italy
| | - Pedro Barata
- University Hospitals Seidman Cancer Center, Cleveland, OH, USA
| | - Alberto Farolfi
- Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori,” Meldola, Italy
| | - Jae Lyun Lee
- University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
| | - Matthew I Milowsky
- University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA
| | - Charlotte Stahlfeld
- Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Leonard Appleman
- Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Joseph W Kim
- Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA
| | - Dory Freeman
- Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA
| | - Toni K Choueiri
- Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA
| | - Philippe E Spiess
- Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA
| | - Andrea Necchi
- Department of Genitourinary Oncology, Vita-Salute San Raffaele University, Milan, Italy
| | - Andrea B Apolo
- Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Guru P Sonpavde
- Division of Medical Oncology, Advent Health Cancer Institute, Orlando, FL, USA
| |
Collapse
|
3
|
Velev M, Dalban C, Chevreau C, Gravis G, Negrier S, Laguerre B, Gross-Goupil M, Ladoire S, Borchiellini D, Geoffrois L, Joly F, Priou F, Barthelemy P, Laramas M, Narciso B, Thiery-Vuillemin A, Berdah JF, Ferrari V, Dominique Thomas Q, Mione C, Curcio H, Oudard S, Tantot F, Escudier B, Chabaud S, Albiges L, Thibault C. Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study. Eur J Cancer 2023; 182:66-76. [PMID: 36746010 DOI: 10.1016/j.ejca.2022.12.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2022] [Revised: 12/29/2022] [Accepted: 12/31/2022] [Indexed: 01/15/2023]
Abstract
INTRODUCTION Bone metastases (BM) in renal cell carcinoma (RCC) are associated with a poor prognosis based on retrospective studies evaluating antiangiogenic agents. Few data are available regarding immune checkpoint inhibitors (ICI) in patients with bone metastatic RCC. NIVOREN is a multicentre prospective study in which patients were treated with nivolumab after the failure of antiangiogenic agents. We aim to assess the impact of BM on prognosis, and the efficacy and safety of nivolumab in patients enrolled in the NIVOREN trial. MATERIALS AND METHODS All patients with BM at inclusion were included in our study. The primary endpoint was overall survival (OS). Secondary endpoints were progression-free survival (PFS), objective response rate (ORR), safety, and skeletal-related events (SRE). RESULTS Among 720 patients treated with nivolumab, 194 presented BM at inclusion. The median follow-up was 23.9 months. Median OS was 17.9 months in patients with BM versus 26.1 months in patients without BM (p = 0.0023). The difference was not statistically significant after adjustment (p = 0.0707). The median PFS was shorter in patients with BM even after adjustment (2.8 versus 4.6 months, p = 0.0045), as well as the ORR (14.8% versus 23.3%). SRE occurred for 36% of patients with BM. A post-hoc analysis evaluating the impact of bone-targeting agents (BTA) on SRE incidence showed a significant benefit of BTA on the incidence of SRE (OR = 0.367, CI95% [0.151-0.895]). CONCLUSION Nivolumab is associated with shorter PFS, and lower ORR in RCC patients with BM. Our study suggests that BTA in association with immunotherapy decreases the incidence of SRE.
Collapse
Affiliation(s)
- Maud Velev
- Departement of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, APHP-Centre, Service d'oncologie médicale, Université Paris Cité, 20 rue Leblanc, 75015, Paris, France.
| | - Cécile Dalban
- Centre Léon Bérard Direction de la Recherche Clinique et de l'Innovation, 28 Prom. Léa et Napoléon Bullukian, 69008, Lyon, France.
| | - Christine Chevreau
- Institut Universitaire du Cancer Toulouse-Oncopole, Service d'oncologie médicale, 1 Av. Irène Joliot-Curie, 31100, Toulouse, France.
| | - Gwenaelle Gravis
- Institut Paoli Calmettes, Service d'oncologie médicale, 232 Bd de Sainte-Marguerite, 13009, Marseille, France.
| | - Sylvie Negrier
- Centre Léon Bérard, université Lyon I, Service oncologie médicale, 28 Prom. Léa et Napoléon Bullukian, 69008, Lyon, France.
| | - Brigitte Laguerre
- Centre Eugene Marquis, Service d'oncologie médicale, Av. de la Bataille Flandres-Dunkerque CS 44229, 35000, Rennes, France.
| | - Marine Gross-Goupil
- Bordeaux University Hospital, Service d'oncologie medicale, Hôpital Pellegrin, Pl. Amélie Raba Léon, 33000, Bordeaux, France.
| | - Sylvain Ladoire
- Centre Georges François Leclerc, Service d'oncologie médicale, 1 Rue du Professeur Marion, 21000, Dijon, France.
| | - Delphine Borchiellini
- Centre Antoine Lacassagne, Université Côte d'Azur, Service d'oncologie médicale, 33 Av. de Valombrose, 06100, Nice, France.
| | - Lionnel Geoffrois
- Institut de Cancérologie de Lorraine, Service d'oncologie médicale, 6 Av. de Bourgogne, Institut de Cancérologie de Lorraine, 54519, Vandoeuvre-lès-Nancy, France.
| | - Florence Joly
- Centre François Baclesse, Service d'oncologie médicale, 3 Av. du Général Harris, 14000, Caen, France.
| | - Frank Priou
- Centre Hospitalier de Vendée, Service d'oncologie médicale, Bd Stéphane Moreau, 85000, La Roche sur Yon, France.
| | - Philippe Barthelemy
- Institut de Cancérologie Strasbourg Europe, Service d'oncologie médicale, 17 Rue Albert Calmette, 67200, Strasbourg, France.
| | - Mathieu Laramas
- Grenoble Alpes University Hospital, Grenoble, Service d'oncologie médicale, Av. des Maquis du Grésivaudan, 38700 La Tronche, France.
| | - Berangère Narciso
- Tours University Hospital, Service d'oncologie médicale, 2 Bd Tonnellé, 37000, Tours, France.
| | - Antoine Thiery-Vuillemin
- Hôpital Jean-Minjoz, Service d'oncologie médicale, 3 Bd Alexandre Fleming, 25000, Besançon, France.
| | - Jean-François Berdah
- Centre Hospitalier de Hyères, Service d'oncologie médicale, Centre hospitalier d'Ajaccio, 27 Av. Impératrice Eugénie, 20000 Ajaccio, France.
| | - Victoria Ferrari
- Centre Antoine Lacassagne, Université Côte d'Azur, Service d'oncologie médicale, 33 Av. de Valombrose, 06100, Nice, France.
| | - Quentin Dominique Thomas
- Departement of Medical Oncology, Institut du Cancer de Montpellier, Montpellier University, Service d'oncologie médicale, Parc Euromédecine, 208 Av. des Apothicaires, 34090, Montpellier, France.
| | - Cécile Mione
- Université Clermont-Ferrand, 28 Pl. Henri Dunant, 63000, Clermont-Ferrand, France.
| | - Hubert Curcio
- Centre François Baclesse, Service d'oncologie médicale, 3 Av. du Général Harris, 14000, Caen, France
| | - Stephane Oudard
- Departement of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, APHP-Centre, Université Paris Cité, Service d'oncologie médicale, 20 rue Leblanc, 75015, Paris, France.
| | | | - Bernard Escudier
- Gustave Roussy Cancer Campus, Université Paris-Saclay, Service d'oncologie médicale, 114 Rue Edouard Vaillant, 94805, Villejuif, France.
| | | | - Laurence Albiges
- Gustave Roussy Cancer Campus, Université Paris-Saclay, Service d'oncologie médicale, 114 Rue Edouard Vaillant, 94805, Villejuif, France.
| | - Constance Thibault
- Departement of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, APHP-Centre, Université Paris Cité, Service d'oncologie médicale, 20 rue Leblanc, 75015, Paris, France.
| |
Collapse
|
4
|
El Zarif T, Nassar A, Jiang L, Pond GR, Zhuang T, Velev M, Hahn AW, Buti S, Álvarez P, McKay RR, Vincenzi B, El-Am E, Hui G, Lee JL, Mouhieddine TH, Milowsky MI, Matthews H, Barata PC, Apolo AB, Sonpavde GP. Safety and efficacy of immune checkpoint inhibitors (ICI) in advanced penile squamous cell carcinoma (PeCa): An international study from the Global Society of Rare Genitourinary Tumors (GSRGT). J Clin Oncol 2023. [DOI: 10.1200/jco.2023.41.6_suppl.5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/18/2023] Open
Abstract
5 Background: Management options for patients (pts) with advanced (locally advanced or metastatic) PeCa are limited. The GSRGT assembled an international cohort of pts with advanced PeCa treated with ICI to evaluate toxicity and clinical outcomes. Methods: We retrospectively collected data on pts with advanced PeCa receiving ≥1 cycle of ICI between 2015-2022 at 18 medical centers in the US, Europe, and Asia. Immune-related adverse events (irAE) were graded per the Common Terminology Criteria for Adverse Events v5.0. Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method. Objective response rate (ORR) was determined by the clinical investigator per RECIST 1.1 criteria, whenever feasible. Results: Among 72 pts with advanced PeCa treated with ICI, 24 (33%) were Hispanic and 7 (10%) were Black. 60 (83%) pts had metastases while the remainder had locally advanced disease. The median age was 64 (inter-quartile range (IQR): 54,70) years and 48 (67%) had ECOG performance status ≥1. Most pts (n=60, 83%) were treated in the ≥2nd line setting and received pembrolizumab (n=23), nivolumab (n=15), cemiplimab (n=15), nivolumab and ipilimumab (n=7), or other anti-PD1/L1-based therapies (n=12). Among 37 pts with available data on HPV status, 24 (65%) were HPV+. 3 (4%) pts were HIV+. irAE of any grade occurred in 18 (25%) pts, 7 (10%) were grade ≥3, 7 (10%) required steroids, 6 (9%) required hospitalization, and 8 (11%) led to treatment discontinuation. The median OS and 24-month OS and median PFS and 24-month PFS were 9.4 (95%CI: 6.8, 12.8) months and 19.3% (95%CI: 9.2, 32.1) and 2.8 (95%CI: 2.1, 3.9) months and 11.2 % (95%CI: 4.9, 20.2), respectively. Among 66 pts evaluable for response, ORR was 7/66 (11%) (2 with complete response, 5 with partial response), and 16 (24%) pts had stable disease for a disease control rate of 35%. The median duration of response was 7.9 (IQR: 3, not reached) months. Conclusions: In the largest retrospective cohort of ICI-treated advanced PeCa, ICI showed no new safety signals, however, overall anti-tumor activity was limited. Future translational studies are needed to identify pts that are more likely to derive clinical benefit from ICI.
Collapse
Affiliation(s)
| | | | | | | | - Tony Zhuang
- Department of Medicine, Emory University School of Medicine, Atlanta, GA
| | | | | | - Sebastiano Buti
- Department of Medicine and Surgery, University of Parma, Parma, Italy
| | - Pablo Álvarez
- 12 de Octubre University Hospital, Medical Oncology Department, Madrid, Spain
| | - Rana R. McKay
- Moores Cancer Center, University of California San Diego, La Jolla, CA
| | | | | | | | - Jae-Lyun Lee
- Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
| | | | - Matthew I. Milowsky
- University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC
| | | | - Pedro C. Barata
- Department of Internal Medicine, University Hospitals Seidman Cancer Center, Cleveland, OH
| | | | | |
Collapse
|
5
|
Flippot R, Telli T, Velev M, Flechon A, Turpin L, Bergman AM, Turco F, Fendler WP, Giraudet AL, Montravers F, Vogel WV, Gillessen S, Berardi S, Herrmann K, Kryza D, Paone G, Garcia C, Foulon S, Pages A, Fizazi K. Activity of lutetium-177 PSMA (Lu-PSMA) and determinants of outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with cabazitaxel: The PACAP study. J Clin Oncol 2023. [DOI: 10.1200/jco.2023.41.6_suppl.180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/15/2023] Open
Abstract
180 Background: Cabazitaxel and Lu-PSMA both improved survival in patients with mCRPC after docetaxel and an androgen receptor pathway inhibitor (ARPI), but there is limited data regarding Lu-PSMA activity after cabazitaxel. We aimed at assessing activity of Lu-PSMA and determinants of outcomes in this setting. Methods: Consecutive mCRPC patients from 6 European centers treated with Lu-PSMA after cabazitaxel were included in this retrospective study. Endpoints included radiographic progression-free survival (rPFS), time to PSA progression (PSA-TTP), PSA decline, objective response, overall survival, and safety. Results: Of 101 patients included (median age 67y), 64% had ISUP grade 4-5 disease; 71% had bone +/- nodal (LN) metastases, 22% visceral metastases, 7% LN only. All patients and 92% had received previous docetaxel and a prior ARPI (≥ 2 in 47%) before cabazitaxel respectively. Patients had received a median number of 6 cabazitaxel cycles (range 1-26). DNA damage repair alterations (DDR) were found in 11/48 (23%) patients with available testing. Patients received a median number of 3 Lu-PSMA cycles (range 1-14). With a median follow-up of 5.7 months, the median rPFS from Lu-PSMA initiation was 4.3 months (m, 95%CI 3.2-5.7) and median PSA-TTP was 3.5 m (95%CI 3.0-4.5). Overall, 44 patients (44%) experienced a PSA decline ≥ 50% (PSA50), 54 (53%) ≥ 30% (PSA30), and 67 (66%) any PSA decline. Objective response rate was 34%. Baseline characteristics associated with shorter rPFS on Lu-PSMA included ISUP grade 4-5 disease (median rPFS of 3.5 vs. 7.2m, p=0.02) and a time to castration resistance < 12 months (3.1m vs. 4.5m, p=0.04). Patients with LN only had longer rPFS compared to those with bone and visceral metastases (median NR vs. 3.6 and 3.7m, respectively, p=0.02). There was no association between activity of Lu-PSMA and DNA damage repair alterations, duration of previous cabazitaxel therapy, and number of previous ARPI. During Lu-PSMA, a profound PSA decline was associated with longer rPFS: patients achieving PSA50, PSA30 or any PSA decline had respective median rPFS rates of 9.0, 8.3 and 6.2 months, while those who did not experience any PSA decline had a median rPFS of only 2.6 months. Conclusions: Lu-PSMA demonstrated substantial PSA decline but limited duration of response after cabazitaxel in a real-life setting. Adverse baseline characteristics and absence of PSA decline may help early identification of poor responders.
Collapse
Affiliation(s)
- Ronan Flippot
- Department of Medical Oncology, Gustave Roussy, Villejuif, France
| | - Tugce Telli
- Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany
| | | | | | - Lea Turpin
- Tenon University Hospital, APHP, Paris, France
| | | | - Fabio Turco
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - Wolfgang Peter Fendler
- Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | | | | | | | - Silke Gillessen
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - Simona Berardi
- Swiss Group for Clinical Cancer Research, Bern, Switzerland
| | - Ken Herrmann
- Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | | | - Gaetano Paone
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | | | | | | | | |
Collapse
|
6
|
Velev M, Baroudjian B, Pruvost R, De Martin E, Laparra A, Babai S, Teysseire S, Danlos FX, Albiges L, Bernigaud C, Benderra MA, Pradère P, Zaidan M, Decroisette C, Fallah F, Matergia G, Lavaud P, Jantzem H, Atzenhoffer M, Buyse V, Ammari S, Robert C, Champiat S, Messayke S, Marabelle A, Guettier C, Lebbe C, Lambotte O, Michot JM. Immune-related generalised oedema - A new category of adverse events with immune checkpoint inhibitors. Eur J Cancer 2023; 179:28-47. [PMID: 36473326 DOI: 10.1016/j.ejca.2022.11.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2022] [Revised: 10/31/2022] [Accepted: 11/01/2022] [Indexed: 11/15/2022]
Abstract
BACKGROUND Generalised oedema was occasionally reported associated with immune checkpoint inhibitors (ICPIs). The purpose of this study is to investigate immune-related generalised oedema (ir-GE) drug related to ICPI, through frequency, clinical and pathological characteristics, and patient's outcome. PATIENTS AND METHODS Objectives of the study were to report on ir-GE associated with ICPI to define frequency, associated signs and symptoms, pathological characteristics, severity, and response to corticosteroids. To be included in the study, adult patients had to have ir-GE related to ICPI with certain or likely link, without any other known causes of generalised oedema. The study design was observational, over the period 2014-2020, from pharmacovigilance databases in France, including the prospective Registre des Effets Indésirables Sévères des Anticorps Monoclonaux Immunomodulateurs en Cancérologie (REISAMIC) registry. Calculation of the frequency of ir-GE was restricted to the prospective REISAMIC registry. RESULTS Over 6633 screened patients, 20 had ir-GE confirmed drug related to ICPI. Based on the prospective REISAMIC registry, the frequency of ir-GE was 0.19% of ICPI-treated patients (3 cases out of 1598 screened patients). The 20 patients with ir-GE had a median (range) age of 62 (26-81) years, most frequent tumour types were melanoma (n = 9; 45%) and lung cancer (n = 6; 30%). The most frequent localisations of oedema were peripheral (n = 17; 85%), pleural (n = 13; 65%), and peritoneal (n = 10; 50%). Polyserositis was observed in 11 (55%) patients. The median (range) weight gain per patient was 9 (2-30) kg. Associated signs and symptoms met criteria for capillary leak syndrome (n = 4; 20%), sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) (n = 3; 15%), or subcutaneous autoimmune syndrome (n = 2; 10%). Corticosteroids were administered to 15 patients; of them, 10 (67%) improved clinically after corticosteroids. Based on CTCAEV5.0, the highest severity of ir-GE was grade ≥4 in 11 (55%) patients and four (20%) patients died due to ir-GE. CONCLUSIONS Generalised immune system-related oedema is a new category of adverse event with immune checkpoint inhibitors and is often associated with a life-threatening condition. The pathophysiology may in some cases be related to endothelial dysfunctions, such as SOS/VOD or capillary leak syndrome.
Collapse
Affiliation(s)
- Maud Velev
- Gustave Roussy - Paris-Saclay University, Département d'Innovation Thérapeutique et Essais Précoces, 94800 Villejuif, France
| | - Barouyr Baroudjian
- Assistance Publique - Hôpitaux de Paris, Saint-Louis Hospital, Dermatology Department, 75010 Paris, France
| | - Roxane Pruvost
- Gustave Roussy - Paris-Saclay University, Département d'Innovation Thérapeutique et Essais Précoces, 94800 Villejuif, France
| | - Eleonora De Martin
- Assistance Publique - Hôpitaux de Paris, Paul-Brousse Hospital, Department of Hepatology, Centre Hépato-Biliaire, INSERM 1193, 94800 Villejuif, France
| | - Ariane Laparra
- Gustave Roussy - Paris-Saclay University, Département d'Innovation Thérapeutique et Essais Précoces, 94800 Villejuif, France
| | - Samy Babai
- Assistance Publique - Hôpitaux de Paris, Henri Mondor Hospital, Department of Pharmacovigilance, 94000 Créteil, France
| | - Sandra Teysseire
- Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud Pierre Bénite, Department of Dermatology, 69002 Lyon, France
| | - François-Xavier Danlos
- Gustave Roussy - Paris-Saclay University, Département d'Innovation Thérapeutique et Essais Précoces, 94800 Villejuif, France
| | - Laurence Albiges
- Gustave Roussy - Paris-Saclay University, Department of Medical Oncology, 94800 Villejuif, France
| | - Charlotte Bernigaud
- Assistance Publique - Hôpitaux de Paris, Henri Mondor Hospital, Dermatology Department, 94000 Créteil, France
| | - Marc-Antoine Benderra
- Assistance Publique - Hôpitaux de Paris, Tenon Hospital, Department of Medical Oncology, 75020 Paris, France
| | - Pauline Pradère
- Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France
| | - Mohamad Zaidan
- Assistance Publique - Hôpitaux de Paris, Paris-Saclay University, Bicêtre Hospital, Nephrology Department, 94270 Le Kremlin-Bicêtre, France
| | - Chantal Decroisette
- Centre Hospitalier Annecy Genevois, Department of Medical Oncology, 74374 Pringy, France
| | - Fatma Fallah
- Centre Hospitalier Argenteuil, Department of Medical Oncology, 95107 Argenteuil, France
| | - Gaelle Matergia
- Hôpital-Clinique Claude Bernard, Department of Medical Oncology, 57070 Metz, France
| | - Pernelle Lavaud
- Gustave Roussy - Paris-Saclay University, Department of Medical Oncology, 94800 Villejuif, France
| | - Hélène Jantzem
- Centre Hospitalier Universitaire de Brest, Department of Pharmacovigilance, Centre Régional de Pharmacovigilance, 29609 Brest, France
| | - Marina Atzenhoffer
- Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud Pierre Bénite, Department of Clinical Pharmacology and Pharmacovigilance, 69002 Lyon, France
| | - Véronique Buyse
- O.L.V. van Lourdes Ziekenhuis Waregem, Vijfseweg 150, 8790 Waregem, Belgium; Oncologie, Vijfseweg 150, B-8790 Waregem, Belgium
| | - Samy Ammari
- Gustave Roussy - Paris-Saclay University, Radiology Department, 94800 Villejuif, France
| | - Caroline Robert
- Gustave Roussy - Paris-Saclay University, Department of Medical Oncology, 94800 Villejuif, France
| | - Stéphane Champiat
- Gustave Roussy - Paris-Saclay University, Département d'Innovation Thérapeutique et Essais Précoces, 94800 Villejuif, France
| | - Sabine Messayke
- Gustave Roussy - Paris-Saclay University, Pharmacovigilance Unit, 94800 Villejuif, France
| | - Aurélien Marabelle
- Gustave Roussy - Paris-Saclay University, Département d'Innovation Thérapeutique et Essais Précoces, 94800 Villejuif, France
| | - Catherine Guettier
- Assistance Publique - Hôpitaux de Paris, Paris-Saclay University, Bicêtre Hospital, Department of Pathology, UMR-S 1193, 94270 Le Kremlin Bicêtre, France
| | - Céleste Lebbe
- Assistance Publique - Hôpitaux de Paris, University of Paris, Department of Dermatology, DMU ICARE, Saint Louis Hospital, INSERM U976 HIPI, Team 1, F-75010 Paris, France
| | - Olivier Lambotte
- Assistance Publique - Hôpitaux de Paris, Paris-Saclay University, Bicêtre Hospital, Internal Medicine Department, 94270 Le Kremlin-Bicêtre, France
| | - Jean-Marie Michot
- Gustave Roussy - Paris-Saclay University, Département d'Innovation Thérapeutique et Essais Précoces, 94800 Villejuif, France; Gustave Roussy, INSERM U1170, Université Paris-Saclay, Villejuif, France.
| |
Collapse
|
7
|
Velev M, Dalban C, Chevreau C, Gravis G, Negrier S, Laguerre B, Gross-Goupil M, Ladoire S, Ferrari V, Geoffrois L, Curcio H, Priou F, Thomas QD, Mione C, Barthélémy P, Tantot F, Escudier B, Chabaud S, Albiges L, Thibault C. Efficacy and safety of nivolumab in renal cell carcinoma patients with BONE metastases: Results of the GETUG: AFU 26 nivoren multicenter phase II study. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.6_suppl.342] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
342 Background: Bone metastases (BM) in renal cell carcinoma (RCC) are associated with a poor prognosis based on retrospective studies in which patients were treated with antiangiogenic agents. Since the development of immune checkpoint inhibitors, few data are available regarding the prognosis impact of BM or the efficacy and safety of checkpoint inhibitors in patients with bones metastatic RCC. GETUG-AFU26-NIVOREN (NIVOREN) is a French multicenter prospective study in which patients were treated with nivolumab after failure of one or more antiangiogenic tyrosine kinase inhibitors. We therefore aim to evaluate the impact of BM on prognosis, and the efficacy and safety of nivolumab in patients with BM enrolled in NIVOREN trial. Methods: All adult patients with BM at inclusion were included in our study. The primary endpoint of this ancillary study was overall survival (OS). Secondary endpoints were progression-free survival (PFS), objective response rate (ORR), safety, and skeletal-related events (SRE) in patients with BM. Clinical data were collected prospectively, except for SRE data which were collected retrospectively in a complementary consent report form. Results: Among 720 patients treated with nivolumab in the NIVOREN study, 194 had BM at inclusion. After a median follow-up of 23.9 months, the median OS was 17.9 months in patients with BM versus 26.1 months in patients without BM (HR = 1.42 CI95% [1.13-1.79], p = 0.0023). After adjustment on sex, age, IMDC group and line of treatments, the difference was not significant (HR = 1.24, CI95% [0.98-1.56], p = 0.0707). The median PFS was shorter in patients with BM even after adjustment (2.8 versus 4.6 months, HR = 1.30 CI95% [1.08-1.56]), as well as the ORR (14.8% versus 23.3%). The safety profile was similar between patients with or without BM at inclusion. The incidence of SRE in the BM population was 36% during the treatment period with nivolumab. A post-hoc analysis evaluating the impact of bone-targeting agents in association with nivolumab on SRE incidence was performed. There was a statistically significant benefit in patients treated with bone-targeting agents on the incidence of SRE (OR = 0.367, CI95% [0.151-0.895], p = 0.0276). Conclusions: Nivolumab is associated with shorter OS, PFS, and lower ORR in patients with BM. Our study confirms, in the era of immunotherapy that patients with BM are associated with poorer prognosis and suggests that association with bone-targeting agents decreases the incidence of SRE. Clinical trial information: 2015-004117-24.
Collapse
Affiliation(s)
- Maud Velev
- Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France
| | | | | | - Gwenaelle Gravis
- Department of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille Université, CRCM, Marseille, France
| | | | | | - Marine Gross-Goupil
- Centre Hospitalier Universitaire de Bordeaux-Hôpital Saint-André, Bordeaux, France
| | | | | | | | | | - Frank Priou
- Centre Hospitalier de Vendée, La Roche Sur Yon, France
| | | | - Cécile Mione
- Université Clermont-Ferrand, Clermont-Ferrand, France
| | | | | | | | | | - Laurence Albiges
- Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France
| | - Constance Thibault
- Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France
| |
Collapse
|
8
|
Velev M, Puszkiel A, Blanchet B, de Percin S, Delanoy N, Medioni J, Gervais C, Balakirouchenane D, Khoudour N, Pautier P, Leary A, Ajgal Z, Hirsch L, Goldwasser F, Alexandre J, Beinse G. Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study. Pharmaceuticals (Basel) 2021; 14:ph14080804. [PMID: 34451901 PMCID: PMC8399031 DOI: 10.3390/ph14080804] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2021] [Revised: 08/05/2021] [Accepted: 08/12/2021] [Indexed: 12/27/2022] Open
Abstract
Factors associated with olaparib toxicity remain unknown in ovarian cancer patients. The large inter-individual variability in olaparib pharmacokinetics could contribute to the onset of early significant adverse events (SAE). We aimed to retrospectively analyze the pharmacokinetic/pharmacodynamic relationship for toxicity in ovarian cancer patients from “real life” data. The clinical endpoint was the onset of SAE (grade III/IV toxicity or dose reduction/discontinuation). Plasma olaparib concentration was assayed using liquid chromatography at any time over the dosing interval. Trough concentrations (CminPred) were estimated using a population pharmacokinetic model. The association between toxicity and clinical characteristics or CminPred was assessed by logistic regression and non-parametric statistical tests. Twenty-seven patients were included, among whom 13 (48%) experienced SAE during the first six months of treatment. Olaparib CminPred was the only covariate significantly associated with increased risk of SAE onset (odds ratio = 1.31, 95% CI = [1.10; 1.57], for each additional 1000 ng/mL). The ROC curve identified a threshold of CminPred = 2500 ng/mL for prediction of SAE onset (sensitivity/specificity 0.62 and 1.00, respectively). This study highlights a significant association between olaparib plasma exposure and SAE onset and identified the threshold of 2500 ng/mL trough concentration as potentially useful to guide dose adjustment in ovarian cancer patients.
Collapse
Affiliation(s)
- Maud Velev
- Department of Medical Oncology, Cochin University Hospital, Assistance Publique-Hôpitaux de Paris, 75014 Paris, France; (M.V.); (S.d.P.); (Z.A.); (L.H.); (F.G.); (G.B.)
| | - Alicja Puszkiel
- Department of Pharmacokinetics and Pharmacochemistry, Cochin University Hospital, Assistance Publique-Hôpitaux de Paris, 75014 Paris, France; (A.P.); (B.B.); (D.B.); (N.K.)
- INSERM UMR-S1144, Faculté de Pharmacie, Université de Paris, 75006 Paris, France
| | - Benoit Blanchet
- Department of Pharmacokinetics and Pharmacochemistry, Cochin University Hospital, Assistance Publique-Hôpitaux de Paris, 75014 Paris, France; (A.P.); (B.B.); (D.B.); (N.K.)
- UMR8038 CNRS, U1268 INSERM, Faculté de Pharmacie, Université de Paris, PRES Sorbonne Paris Cité, CARPEM, 75006 Paris, France
| | - Sixtine de Percin
- Department of Medical Oncology, Cochin University Hospital, Assistance Publique-Hôpitaux de Paris, 75014 Paris, France; (M.V.); (S.d.P.); (Z.A.); (L.H.); (F.G.); (G.B.)
| | - Nicolas Delanoy
- Department of Medical Oncology, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France; (N.D.); (J.M.); (C.G.)
| | - Jacques Medioni
- Department of Medical Oncology, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France; (N.D.); (J.M.); (C.G.)
| | - Claire Gervais
- Department of Medical Oncology, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France; (N.D.); (J.M.); (C.G.)
| | - David Balakirouchenane
- Department of Pharmacokinetics and Pharmacochemistry, Cochin University Hospital, Assistance Publique-Hôpitaux de Paris, 75014 Paris, France; (A.P.); (B.B.); (D.B.); (N.K.)
| | - Nihel Khoudour
- Department of Pharmacokinetics and Pharmacochemistry, Cochin University Hospital, Assistance Publique-Hôpitaux de Paris, 75014 Paris, France; (A.P.); (B.B.); (D.B.); (N.K.)
| | - Patricia Pautier
- Gustave Roussy Cancer Center, Department of Medical Oncology, Université Paris-Saclay, 94805 Villejuif, France; (P.P.); (A.L.)
| | - Alexandra Leary
- Gustave Roussy Cancer Center, Department of Medical Oncology, Université Paris-Saclay, 94805 Villejuif, France; (P.P.); (A.L.)
| | - Zahra Ajgal
- Department of Medical Oncology, Cochin University Hospital, Assistance Publique-Hôpitaux de Paris, 75014 Paris, France; (M.V.); (S.d.P.); (Z.A.); (L.H.); (F.G.); (G.B.)
| | - Laure Hirsch
- Department of Medical Oncology, Cochin University Hospital, Assistance Publique-Hôpitaux de Paris, 75014 Paris, France; (M.V.); (S.d.P.); (Z.A.); (L.H.); (F.G.); (G.B.)
| | - François Goldwasser
- Department of Medical Oncology, Cochin University Hospital, Assistance Publique-Hôpitaux de Paris, 75014 Paris, France; (M.V.); (S.d.P.); (Z.A.); (L.H.); (F.G.); (G.B.)
| | - Jerome Alexandre
- Department of Medical Oncology, Cochin University Hospital, Assistance Publique-Hôpitaux de Paris, 75014 Paris, France; (M.V.); (S.d.P.); (Z.A.); (L.H.); (F.G.); (G.B.)
- Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Université, Inserm, Team Personalized Medicine, Pharmacogenomics and Therapeutic Optimization (MEPPOT), 75006 Paris, France
- Correspondence: ; Tel.: +33-01-(58)-414141
| | - Guillaume Beinse
- Department of Medical Oncology, Cochin University Hospital, Assistance Publique-Hôpitaux de Paris, 75014 Paris, France; (M.V.); (S.d.P.); (Z.A.); (L.H.); (F.G.); (G.B.)
- Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Université, Inserm, Team Personalized Medicine, Pharmacogenomics and Therapeutic Optimization (MEPPOT), 75006 Paris, France
| |
Collapse
|
9
|
Sroussi M, De Percin S, Grecea A, Benderra M, Velev M, Akla S, Lezghed N, Dumont S, Le Péchoux C, Honore C, Haddag L, Faron M, Terrier P, Mir O, Le Cesne A. Pazopanib in advanced or metastatic synovial sarcoma: The Gustave Roussy experience. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy299.040] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
10
|
Oudard S, Velev M, Belhadj Y, Vano Y, Thibault C. [Treatment of metastatic prostate cancer: what recent progress?]. Rev Prat 2018; 68:707-712. [PMID: 30869315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Affiliation(s)
- Stéphane Oudard
- Service de cancérologie médicale, Hôpital européen Georges-Pompidou, AP-HP, université René-Descartes Paris-5, groupe hospitalier Ouest Parisien, Paris, France
| | - Maud Velev
- Service de cancérologie médicale, Hôpital européen Georges-Pompidou, AP-HP, université René-Descartes Paris-5, groupe hospitalier Ouest Parisien, Paris, France
| | - Yassine Belhadj
- Service de cancérologie médicale, Hôpital européen Georges-Pompidou, AP-HP, université René-Descartes Paris-5, groupe hospitalier Ouest Parisien, Paris, France
| | - Yann Vano
- Service de cancérologie médicale, Hôpital européen Georges-Pompidou, AP-HP, université René-Descartes Paris-5, groupe hospitalier Ouest Parisien, Paris, France
| | - Constance Thibault
- Service de cancérologie médicale, Hôpital européen Georges-Pompidou, AP-HP, université René-Descartes Paris-5, groupe hospitalier Ouest Parisien, Paris, France
| |
Collapse
|
11
|
Karagyozov I, Gerganova A, Velev M. [LOCALLY ADVANCED CERVICAL CANCER IN THE PUERPERIUM--CASE REPORT]. Akush Ginekol (Sofiia) 2016; 55:39-42. [PMID: 27514145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
The cervical cancer is the most common gynaecological neoplasma during pregnancy. The average frequency during pregnancy and 1 year post partum is around 1 case per 2 200 pregnancies. The authors present a case of locally advanced cervical cancer (IV stage), diagnosed 30 days after Cesarean section. 5-years survival of this stage is 15%.
Collapse
|
12
|
Bliznashki I, Minev M, Mikhova A, Velev M. [A rare case of Gardner's syndrome complicated with rectal carcinoma]. Khirurgiia (Mosk) 2007:60-63. [PMID: 18437113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Gardner's syndrome is a rare variant of the Familial Adenomatous Polyposis (FAP) in which affected individuals develop thousands of polyps within the gastrointestinal tract, with a 100 % risk of eventual malignant change. They also have a variety of extraintestinal abnormalities - various soft and hard tissues tumors like fibroma, osteoma, epidermoid cysts, sebaceous cysts on the scalp. Gardner's syndrome is an autosomal dominant disease, caused by mutations in APC ( adenomatous polyposis coli ) gene, which is located in chromosomal locus 5q21- q22. Firstly it has been described in 1953 by Gardner and Richards. They have investigated a family of 51 members with polyposis, some of them with multiple epidermoid cysts, fibromas and jaw osteomas. Eight of them have died by colorectal carcinoma. If undetected or untreated virtually all patients develop colonic carcinoma at a young age. Due to this high risk of malignancy the patients with Gardner's syndrome usually undergo surgical treatment by total or subtotal proctocolectomy. We report a case with Gardner's syndrome - a 36 year-old male who has been operated on in Department of Surgery in Vth city clinical hospital in October 2003. He had multiple adenomatous polyposis of colon, rectal cancer, osteomas of skull bones, subcutaneous fibromas and lipomas. We discovered also by ultrasound examination a polyp of gall bladder. His father has had also multiple polyposis with malignancy and metastatic lesions and he has died at age of 49 years. We performed total proctocolectomy with definitive iliac anus and cholecystectomy.
Collapse
|
13
|
Georgiev D, Karag'ozov I, Velev M, Makaveeva V. [Three cases of vaginal adenosis after topical 5-fluorouracil therapy for vaginal HPV-associated lesions]. Akush Ginekol (Sofiia) 2006; 45:59-61. [PMID: 16889191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
Three cases of vaginal adenosis after topical 5-fluorouracil therapy for vaginal HPV-associated lesions are reported. Three patients with colposcopic, histologic and viral evidences for subclinical papillomavirus infection (in combination with low-grade vaginal intraepithelial neoplasia in of them) are treated with 5-FU. In follow-up control examinations persistent ulcerations were found without regression after applied therapy. By colposcopic and histologic examinations vaginal adenosis was proved without histories of intrautering DES exposure. After the destructive therapy the reported lesions were regressed without appearance of new lesions in follow-up control examinations. The application of 5-fluorouracil has to be used only in cases of recurrent vaginal warts and in cases of high-grade vaginal intraepithelial neoplasia with strict folow-up cytological and colposcopic control examinations.
Collapse
|
14
|
Krŭstev N, Mendizova A, Velev M. [Hemobilia caused by gallbladder's polyps in liver cirrhosis]. Khirurgiia (Mosk) 2003; 58:42-4. [PMID: 12515035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/28/2023]
Abstract
Extremely unusual cause of hemobilia from polypus of the Gallbladder in 29 years old patient with liver cirrhosis is reported. The patient died with clinical features of hepatic encephalopathy. The olygosympthomatic clinical course is the reason for unrecognized hemobilia. The ultrasonographic diagnosis was "cholelithiasis" instead of gallbladder's polypus and endoscopy established large ulcer in the duodenum. The role of hemorrhagic diathesis in chronic liver disease is discussed. As is the extent of liver cirrhosis, cholestasis and hepatic encephalopathy deterioration caused by bleeding. Whether timely cholecystectomy could change the course and prognosis of chronic liver disease is also discussed.
Collapse
|